Bristol Myers Squibb to acquire Orbital Therapeutics for $1.5 billion - Investing.com India
Investing.com Indiaarrow_outwardBristol Myers Squibb to buy Orbital Therapeutics for $1.5B in cash (BMY:NYSE)
Seeking Alphaarrow_outwardBristol Myers joins in vivo CAR-T race with $1.5B Orbital acquisition
Endpoints Newsarrow_outwardBristol-Myers Squibb to Acquire Orbital Therapeutics for $1.5 Billion
MarketScreenerarrow_outwardBristol Myers buys Orbital Therapeutics for $1.5 billion By Reuters - Investing.com
Investing.comarrow_outwardBristol Myers buys Orbital Therapeutics for $1.5 billion - Reuters
Reutersarrow_outwardBristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics - Business Wire
Business Wirearrow_outwardOrbital Therapeutics Appoints Adam Raff, M.D., Ph.D., as Senior Vice President, Clinical Development - citybiz
Citybizarrow_outwardOrbital Therapeutics Presents Non-Human Primate Data for In Vivo CAR-T Therapy with Potential Best-in-Class Profile for Autoimmune Disease - BioSpace
BioSpacearrow_outwardNew preclinical data support further development of Orbital Therapeuticsโ OTX-201 - BioWorld MedTech
BioWorld MedTecharrow_outward(PDF) Diagnostic and Therapeutic Approaches of Orbital Inflammatory Disease: A Systematic Review - researchgate.net
Researchgate.netarrow_outwardOrbital Therapeutics Appoints Geno Germano, Biopharma Veteran, to its Board of Directors - Yahoo Finance
Yahoo Financearrow_outwardRNA startup Orna Therapeutics cuts more jobs - statnews.com
Statnews.comarrow_outwardOrbital Therapeutics names biopharma vet Ron Philip as CEO | Biotechnology | The Pharmaletter - The Pharma Letter
The Pharma Letterarrow_outwardSpark Therapeutics CEO departs to lead another life sciences company - The Business Journals
The Business Journalsarrow_outwardIn vivo Car-T heads for the clinic, but itโs not Sanaโs | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Oncology Pipelinearrow_outwardSecarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics - News-Medical
News-Medicalarrow_outwardBilateral orbital plasmacytomas as first sign of extramedullary progression post CAR-T therapy: case report and literature review - Frontiers
Frontiersarrow_outwardOrbital raises $270m investment for advancement of RNA medicines - Pharmaceutical Technology
Pharmaceutical Technologyarrow_outwardOrbital Therapeutics raises $270M series A for next-gen RNA meds, loops in 2 more execs - Fierce Biotech
Fierce Biotecharrow_outwardInvesting in Orbital Therapeutics - Andreessen Horowitz
Andreessen Horowitzarrow_outwardOrbital raises $270 million in biotechโs largest Series A round this year - BioPharma Dive
BioPharma Divearrow_outwardOrbital bags $270 million to advance RNA-based therapeutics - FirstWord Pharma
FirstWord Pharmaarrow_outwardOrbital Therapeutics Raises $270M to Bring RNA-Based Medicines to New Heights - MedCity News
MedCity Newsarrow_outwardRNA and Gene Editing Pioneers Launch Orbital Therapeutics - Inside Precision Medicine
Inside Precision Medicinearrow_outwardGyroscope and Orbital to create retinal gene therapy company - PharmaTimes
PharmaTimesarrow_outwardBisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy - BMC Ophthalmology
BMC Ophthalmologyarrow_outwardClinical features and therapeutic responses of idiopathic orbital myositis - Wiley Online Library
Wiley Online Libraryarrow_outwardOrbital inflammatory disease: a diagnostic and therapeutic challenge - Nature
Naturearrow_outward
Orbital Therapeutics close
- 2025-10-10 19:20 event
- 29 sourceslanguage
- 200+ ads_click
- 13 hours ago schedule